PMID: 34985309 PMCID: PMC8800560 DOI: 10
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a
Results: Among 58,464 patients, the median BMI was 28
European atrial fibrillation (AF) guidelines recommend management decisions on adopting a strategy of either rhythm control or rate control, prescribing oral
Each patient in the trial had signs of atrial cardiopathy without apparent atrial fibrillation and had recently experienced a stroke that could not be attributed to atrial
The prevalence of atrial fibrillation (AF) is higher among obese patients
Novel oral anticoagulants (NOACs) are increasingly used as an alternative
Atrial fibrillation (AF) and valvular heart disease (VHD) often coexist, and aortic stenosis is one of the most prevalent VHD subtypes in developed countries, 1, 2, 3 affecting a large proportion of the elderly population
Patients presented with atrial fibrillation (AF) are at increased risk of stroke, and prophylactic treatment with oral anticoagulants (OAC) is central to the management of this common arrhythmia
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults and is associated with an increased risk of thromboembolic stroke; therefore, anticoagulation is the cornerstone of its management (1, 2)
Obesity is an independent risk factor for AF
1, Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation
1,2 Appropriate thromboprophylaxis is an urgent need for stroke prevention in AF
Background The purpose of this meta-analysis was to compare efficacy and safety of direct oral anticoagulants (DOACs) to warfarin for secondary stroke prevention among adult patients with atrial fibrillation and prior stroke
A best evidence topic in cardiac surgery was written according to a structured protocol
Atrial fibrillation with reduced LVEF frequently coexist, and each likely to complicate the course of the other with no clear consensus on how to best treat these patients
Skip to Main Content
056355
5–1% of the general population experience atrial fibrillation (AF), a sustained arrhythmia frequently seen in clinical practice, that significantly increases the incidence of thromboembolism when associated with VHD []
We compared dementia development among users of NOACs or warfarin in patients with atrial fibrillation with no prior neurological diagnoses